GILD Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 27.44% compared to Gilead Sciences, Inc.'s net margin of 13.47%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Amgen, Inc.'s return on equity of 102.03%.

Gilead Sciences, Inc. has a consensus price target of $157.43, signalling upside risk potential of 9.02%. On the other hand Amgen, Inc. has an analysts' consensus of $350.03 which suggests that it could fall by -3.07%. Given that Gilead Sciences, Inc. has higher upside potential than Amgen, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Amgen, Inc..

Gilead Sciences, Inc. has a beta of 0.366, which suggesting that the stock is 63.44% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.886%.

Gilead Sciences, Inc. has a quarterly dividend of $0.82 per share corresponding to a yield of 2.21%. Amgen, Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $2.52 per share. Gilead Sciences, Inc. pays 46.6% of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $8B, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Gilead Sciences, Inc.'s net income of $2.2B is higher than Amgen, Inc.'s net income of $1.3B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.29x while Amgen, Inc.'s PE ratio is 25.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.16x versus 5.32x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 27.44% compared to Gilead Sciences, Inc.'s net margin of 20.83%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Johnson & Johnson's return on equity of 34.46%.

Gilead Sciences, Inc. has a consensus price target of $157.43, signalling upside risk potential of 9.02%. On the other hand Johnson & Johnson has an analysts' consensus of $240.38 which suggests that it could grow by 0.95%. Given that Gilead Sciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences, Inc. is more attractive than Johnson & Johnson.

Gilead Sciences, Inc. has a beta of 0.366, which suggesting that the stock is 63.44% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Gilead Sciences, Inc. has a quarterly dividend of $0.82 per share corresponding to a yield of 2.21%. Johnson & Johnson offers a yield of 2.18% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences, Inc. pays 46.6% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $8B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Gilead Sciences, Inc.'s net income of $2.2B is lower than Johnson & Johnson's net income of $5.1B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.29x while Johnson & Johnson's PE ratio is 21.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.16x versus 6.14x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 27.44% compared to Gilead Sciences, Inc.'s net margin of 34.4%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Eli Lilly & Co.'s return on equity of 104.39%.

Gilead Sciences, Inc. has a consensus price target of $157.43, signalling upside risk potential of 9.02%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.34 which suggests that it could grow by 29.99%. Given that Eli Lilly & Co. has higher upside potential than Gilead Sciences, Inc., analysts believe Eli Lilly & Co. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.366, which suggesting that the stock is 63.44% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Gilead Sciences, Inc. has a quarterly dividend of $0.82 per share corresponding to a yield of 2.21%. Eli Lilly & Co. offers a yield of 0.67% to investors and pays a quarterly dividend of $1.73 per share. Gilead Sciences, Inc. pays 46.6% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $8B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Gilead Sciences, Inc.'s net income of $2.2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.29x while Eli Lilly & Co.'s PE ratio is 41.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.16x versus 13.00x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 27.44% compared to Gilead Sciences, Inc.'s net margin of -121.83%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Moderna, Inc.'s return on equity of -29.19%.

Gilead Sciences, Inc. has a consensus price target of $157.43, signalling upside risk potential of 9.02%. On the other hand Moderna, Inc. has an analysts' consensus of $43.75 which suggests that it could fall by -18.88%. Given that Gilead Sciences, Inc. has higher upside potential than Moderna, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Moderna, Inc..

Gilead Sciences, Inc. has a beta of 0.366, which suggesting that the stock is 63.44% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.087%.

Gilead Sciences, Inc. has a quarterly dividend of $0.82 per share corresponding to a yield of 2.21%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences, Inc. pays 46.6% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $8B, which are larger than Moderna, Inc. quarterly revenues of $678M. Gilead Sciences, Inc.'s net income of $2.2B is higher than Moderna, Inc.'s net income of -$826M. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.29x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.16x versus 10.79x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.